Lilly Enters $730M Collaboration to Develop GPCR-Targeted Therapies for Diabetes and Metabolic Diseases

　　【Pharmaceutical Network Enterprise News】For many years, continuous innovation in diabetes and metabolic diseases has been Eli Lilly's top priority. Targeting the development of drugs for diabetes and other metabolic diseases, Eli Lilly recently placed a bet on GPCR, achieving a collaboration worth over $700 million.
 

It is reported that Eli Lilly and Company has recently reached a cooperation agreement with Sosei Heptares worth a total of $730 million. Eli Lilly will pay Sosei Heptares an upfront payment of $37 million. The latter may also receive development and commercialization milestones of up to $694 million, as well as tiered royalties on global sales.
 

In this collaboration, Eli Lilly and Company will utilize Sosei's StaR platform to design GPCRs through minimal single-point mutations and leverage its expertise in diabetes and metabolic diseases to develop and commercialize small-molecule drugs targeting G protein-coupled receptors (GPCRs) for the treatment of diabetes and metabolic disorders.
 

Data shows that Sosei Heptares is a company dedicated to developing innovative therapies targeting GPCRs. The company's technology platform includes the stable GPCR technology platform called StaR. This platform introduces point mutations in GPCRs to enhance their thermal stability, allowing them to maintain a stable conformation and original function even when removed from the cellular membrane environment.
 

Sosei Heptares stated that GPCRs are an important class of therapeutic targets, with nearly 400 GPCRs associated with various diseases, and 34% of FDA-approved drugs target GPCRs. However, 56% of GPCR targets remain unexploited, offering significant opportunities for the development of potential "first-in-class" and "best-in-class" therapies. Previously, Sosei Heptares has collaborated with pharmaceutical companies such as AbbVie, AstraZeneca, Roche, GlaxoSmithKline, Novartis, and Pfizer.
 

It is reported that Eli Lilly and Company has a strong presence in the diabetes field. Judging solely from its performance, diabetes is a crucial business for Eli Lilly, contributing $6.826 billion in revenue in the first half of 2022. In the long term, the growth of the company's diabetes business is far from over. Two key hypoglycemic drugs, dulaglutide and empagliflozin, remain powerful, and the GIP/GLP-1 dual receptor agonist tirzepatide is poised for action.
 

A relevant person from Eli Lilly and Company stated that for many years, continuous innovation in diabetes and metabolic diseases has been the company's top priority. They look forward to collaborating with Sosei Heptares and believe that this new partnership will unlock new targets, offering novel treatment methods for these diseases and bringing new therapeutic options to patients.
 

It is reported that recently, Eli Lilly (LLY.US) and Nxera Pharma Co. Ltd announced a collaboration to provide sustainable, high-quality, and affordable human insulin and analogs for at least 1 million patients with type 1 and type 2 diabetes in low- and middle-income countries (most of which are in Africa). Eli Lilly stated that this is the first time the company has offered insulin active pharmaceutical ingredients (API) to Nxera Pharma Co. Ltd at a significantly reduced price. Eli Lilly will also provide technology transfer free of charge, enabling Nxera Pharma Co. Ltd to formulate, fill, and finish insulin vials and cartridges, thereby making the company a trusted manufacturer of these drugs in Africa.
 

Reportedly, besides the diabetes field, Eli Lilly and Company has ventures in the oncology field, autoimmune field, and neurology diseases. Data forecasts that Eli Lilly's revenue in 2023 will be $30.3 billion to $30.8 billion, with earnings per share of $7.65 to $7.85, and adjusted earnings per share of $8.10 to $8.30.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.